Table 1 Treatment schedule for corneal neovascularization method

1

Control

–

2

Bevacizumab (standard)

0.125% w/v

3

Mefloquine (low dose)

0.3% w/v

4

Mefloquine (medium dose)

0.6% w/v

5

Mefloquine (high dose)

1.0% w/v

6

4-Aminopyridine (low dose)

1.0% w/v

7

4-Aminopyridine (medium dose)

2.0% w/v

8

4-Aminopyridine (high dose)

4.0% w/v

9

Lubiprostone (low dose)

0.25% w/v

10

Lubiprostone (medium dose)

0.5% w/v

11

Lubiprostone (high dose)

1.0% w/v